Previous Article | Next Article ![]()
Journal of Bacteriology, February 2007, p. 1399-1406, Vol. 189, No. 4
0021-9193/07/$08.00+0 doi:10.1128/JB.01226-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Josephine R. Chandler,
Thinh Le,
Briana K. Kozlowicz,
Dawn A. Manias, and
Gary M. Dunny*
Department of Microbiology, University of Minnesota, MMC 196, 420 Delaware Street, S.E., Minneapolis, Minnesota 55455
Received 4 August 2006/ Accepted 2 November 2006
|
|
|---|
|
|
|---|
![]() View larger version (30K): [in a new window] |
FIG. 1. Extracellular (A) and intracellular (B) peptide-mediated control circuits in the pCF10 system. (A) Pheromone cCF10 (LVTLVFV) is produced (double arrows) from the chromosome (thin line with broken end) by proteolytic processing of the chromosomal ccfA gene product (3), whereas inhibitor iCF10 (AITLIFI) is produced by processing of the polypeptide encoded by the prgQ gene (38) of pCF10 (thin circle); prgQ is actually the first gene in a long, pheromone-inducible conjugation operon. Either endogenously produced or exogenous cCF10 pheromone can induce expression of Asc10 and other pCF10-encoded conjugation gene products. Pheromone activity of cCF10 is inhibited by iCF10, but previous work has not fully elucidated whether this occurs inside the cell, outside the cell, or in both locations. In a plasmid-containing donor cell, the pCF10-encoded PrgY protein reduces the amount of cCF10 produced, and the cell produces enough iCF10 to neutralize the residual cCF10 that escapes PrgY control (9, 10, 25); this precise balance in opposing activities can be shifted by addition of exogenous cCF10 from recipient cells. (B) Working model for the function of PrgX as the intracellular switch controlling pheromone-inducible conjugation. The protein consists of an N-terminal DNA binding domain (oval) connected by a flexible linker to a central dimerization domain (filled box), which also contains a peptide binding pocket (39). When cCF10 pheromone occupies this pocket, the PrgX C-terminal regulatory domain (represented by a thin, curved line) undergoes a marked shift to allow for interactions of amino acids between positions 295 and 300 with the bound peptide; this displaces a loop in this domain (residues 287 to 294) that is important for PrgX tetramer formation (39). In complexes with iCF10, PrgX amino acids between residues 311 and 315 interact with the bound peptide; this actually stabilizes the position of the tetramer-promoting loop. Tetramers of PrgX are predicted to simultaneously bind two operator sites in pCF10 DNA more stably than a pair of unlinked dimers. One of these operators overlaps the prgQ promoter, such that conjugation is repressed when it is occupied by PrgX (6, 7).
|
Previously published literature suggested that the primary site of competition between the inhibitor and pheromone peptides might be the extracellular pheromone binding proteins (PrgZ in the pCF10 system and TraC in the case of plasmids pAD1 and pPD1) (17) that enhance pheromone uptake at low concentrations, but there was little direct evidence to support this contention. Very recently, we have shown that both cCF10 and iCF10 target PrgX (30). New structural data show that both proteins bind to the same region of PrgX but produce different conformational changes (30). As noted above, in the case of cCF10 binding (39), a subdomain of PrgX immediately adjacent to the loop encompassing residues 287 to 294 changes its structure dramatically. This is due to direct interactions between the bound pheromone and residues 296 to 299 of PrgX. Our recent data (30)show that in iCF10/PrgX complexes, PrgX residues 312 to 315 interact with the bound inhibitor, actually locking the loop encompassing residues 287 to 294 into a tetramer-promoting conformation. In light of these recent data, the extent to which direct interactions of cCF10 and iCF10 with PrgZ modulate the biological activities of these peptides is less clear. In addition, the means by which the specific amino acid sequences of these peptides determine their biological activities are not fully understood.
In the course of several studies of the pCF10 system (6, 7, 10, 29, 30), we have generated isogenic sets of strains containing a transcriptional reporter gene fused to the pheromone-inducible prgQ promoter and expressing various combinations of prgX, prgY, and prgZ in order to better understand the interactions between the products of these genes and the regulatory peptides. Here we report the use of similar reporter strains in a series of genetic and physiological experiments designed to complement recent structural studies (30, 39) by providing data on the functional interactions of cCF10 and iCF10 with the PrgX and PrgZ proteins. We also describe a genetic screen to identify peptide variants of cCF10 with altered biological activities, and we examine the extent to which PrgX and PrgZ affect these activities. The results suggest that the amino acid sequence determinants affecting interactions with PrgX are most important in the activities of both pheromone and inhibitor peptides. Comparative analysis of native and variant peptides also revealed amino acid residues of cCF10 that were important for efficient PrgZ-mediated import.
|
|
|---|
was used for cloning purposes and was grown in Luria-Bertani (LB) broth at 37°C with antibiotics at the following concentrations: erythromycin, 200 µg/ml; kanamycin, 50 µg/ml; and spectinomycin, 50 µg/ml. All bacterial strains and plasmids used in this study are summarized in Table 1. Plasmid pPCR-4, used for mutagenesis of the cCF10-coding sequence, contains the pCF10 prgQ gene cloned into the vector pDL278 with the 3' sequence altered to encode cCF10 instead of the native iCF10 (8, 38). The plasmid pMSP6043-1 expresses PrgZ from a pCF10-derived carrying encoding prgN, -O, -P, -W, and -Z cloned into the vector pDL27 (9); pMSP6043-2, which does not express PrgZ, was made by ligating the EcoRI and PstI fragment from prgN through the middle of prgZ from pINY6023 into the EcoRI and PstI sites of pDL276 in the same orientation as that of pMSP6043-1. Kristich et al. (31) have recently described the integration of the pWV01 repA gene under control of a lactococcal promoter into the upp locus of the E. faecalis chromosome by homologous recombination using an integrative plasmid called pCJK20, where the cloned gene to be integrated is flanked by the 5' and 3' segments of upp to promote recombination. To construct an OG1S derivative with an expressed prgX gene integrated into the chromosome for this study, we used a vector plasmid, pCJK41, that is virtually identical to pCJK20 except that it contains a minor change in the ribosome binding site driving expression of the cloned gene (the sequence from the ribosome binding site to the prgX start codon of the construct used here is AGGAGGTATTATTACATG). The desired integration of prgX into the upp locus was confirmed by PCR and sequencing, and we confirmed expression of levels of PrgX protein comparable to those of cells carrying pCF10 by Western blot analysis (4). |
View this table: [in a new window] |
TABLE 1. Strains and plasmids used in this study
|
-T1R cells (Invitrogen) and screened for production of cCF10 with altered activity.
![]() View larger version (14K): [in a new window] |
FIG. 2. Diagram of pheromone-coding sequence (66 bp) and primers used for oligonucleotide-directed random mutagenesis of plasmid pPCR-4. The coding sequence is derived from the prgQ open reading frame in pCF10 and includes the prgQ promoter (PQ) and altered coding sequence so that cCF10 is expressed instead of the native iCF10 (indicated in checked region of the arrow); the complete DNA sequence for the start codon, the pheromone-coding region, and the four codons immediately upstream is shown. Primers used for random PCR mutagenesis are indicated below; the bracketed region of the prgQ-ccfA degenerate primer indicates the region directed for degenerate base incorporation (see Materials and Methods).
|
Clumping assay.
The fact that pheromone induction can be detected by the formation of visible clumps in donor cell cultures exposed to the peptide (35) served as the basis for the biological assay used to screen mutants. E. coli strains harboring mutated plasmids were individually grown in LB medium for 15 h, and the cells were then centrifuged for 10 min at 11,000 x g and the pheromone activity in the supernatant was assayed. One hundred microliters of the supernatant was added to the first well of a microtiter plate, and twofold serial dilutions were made across a row of wells. Then 10 µl of an overnight culture of E. faecalis OGIRF(pCF10) was added to each well, and the plate was incubated at 37°C with shaking for 2 hours. Culture supernatant from E. coli DH5
-T1R(pPCR-4) was used as a positive control, and wells containing the indicator strain OGIRF(pCF10) and medium were used as a negative control. Pheromone activity was reported as the titer, which is the reciprocal of the highest twofold dilution showing a positive clumping reaction.
ß-Galactosidase assay. Derivatives of E. faecalis OG1RF carrying p043lacZ, containing a pheromone-inducible prgQ-lacZ transcriptional fusion (29) and in some cases a second plasmid (pMSP6043-1, described above) expressing prgZ, were grown overnight in M9-YE medium and then diluted 1:5 into fresh M9-YE medium and grown for an additional 1.5 h before harvesting for ß-galactosidase assay. When indicated, strains were induced immediately after the 1:5 dilution with the indicated concentration of synthetic cCF10, iCF10, or mutated peptide. ß-Galactosidase assays were performed as described previously (29). Results shown are representative of at least two independent experiments done in duplicate on different days.
|
|
|---|
![]() View larger version (15K): [in a new window] |
FIG. 3. Importance of PrgZ and PrgX in cCF10 response. (A) PrgX requirement for cCF10 response as shown by measuring ß-galactosidase induction of plasmid p043lacZ carrying prgX (see text) or a an isogenic plasmid with a deletion in prgX, p043lacZ dX (dX), harbored by either a wild-type strain (OG1Sp) or an isogenic strain with a chromosomal copy of prgX (100-5). Strains grown overnight in M9 medium were diluted 1:5 with no peptides added (black bars), or peptides were added as indicated. cCF10 was added at 10 ng/ml (dark gray bars), and in some cases iCF10 was also added at 10 times (100 ng/ml, light gray bars) or 100 times (1,000 ng/ml, white bars) the cCF10 concentration. (B and C) Response to exogenously added cCF10 in the absence (vector control, gray bars) or presence (pMSP6043-1, white bars) of PrgZ. Cultures grown overnight in M9 medium were diluted 1:5, and cCF10 was added in increasing amounts and harvested at 90 min (B) or added at 5 ng/ml and harvested at the indicated time points (C). Data shown are representative of at least two independent experiments done in duplicate; error bars represent one standard deviation of the mean.
|
Construction of random cCF10 mutants and determination of biological activity. To explore the cCF10 amino acid sequence determinants critical in the functional interactions with PrgZ and PrgX, oligonucleotide-directed random mutagenesis of a chimeric open reading frame encoding the cCF10 peptide (Fig. 2) (see Materials and Methods) in the shuttle plasmid pPCR-4 was performed. Both E. faecalis and E. coli cells carrying this plasmid excrete substantial quantities of cCF10 into the culture medium. To screen these peptides for biological activity, mutated pPCR-4 plasmids were transformed into E. coli, and supernatant preparations from transformants were screened for their ability to cause clumping of a wild-type strain harboring pCF10 (see Materials and Methods). Preliminary analysis indicated that a high percentage of clones expressing no clumping-inducing activity contained stop codons and other severe mutations abolishing peptide production that were uninteresting for our purposes. Therefore, we focused our attention on those clones expressing altered but not abolished activities indicative of production of a variant peptide with amino acid substitutions.
Of 600 clones tested from three independent transformations, 14 unique mutations resulting in culture supernatants yielding reduced activity were identified, and 1 unique mutation (V7I) resulted in increased supernatant activity (Fig. 4). Predicted amino acid substitutions resulting in decreased activity were identified at each position along the cCF10 peptide. Synthetic peptides were made for 10 representative peptides and tested using the same clumping assay to ensure that the observed effects were due to the inherent activity of the peptide as opposed to differences in expression from the E. coli host (Fig. 4). With the exception of V7I, the synthetic peptide activity was similar to the E. coli-produced peptide activity. E. coli supernatants from the strain encoding V7I had increased activity compared with wild-type cCF10, whereas synthetic V7I exhibited activity comparable to that of cCF10. The elevated activity of E. coli-produced V7I may have been due to increased synthesis or more efficient processing of this peptide, but this was not investigated further. All of the peptide variants identified in the genetic screen contained single amino acid substitutions, with the exception of L4I,F6L. For this variant, we also identified each of the corresponding single substitutions in separate clones, and the activity of the double variant was approximately what would be predicted from independent additive effects of the single substitutions (Fig. 4). It was considered possible that some of the peptides with very low pheromone activity might actually act as cCF10 inhibitors, but we were unable to detect any inhibitory activity when responder cells were treated with mixtures of cCF10 and excess amounts of the test peptides (data not shown).
![]() View larger version (14K): [in a new window] |
FIG. 4. Activity of cCF10 and variant peptides to induce clumping of OG1RF(pCF10) cultures. Activity was measured as the reciprocal of the highest dilution of E. coli-produced or synthetically derived cCF10 or mutant derivatives to aggregate an OG1RF(pCF10) indicator strain. The relative amounts of pheromone activity are representative of at least two independent experiments. The peptide LVTLVF- (V7 ) was not found in the original assay but was synthesized and tested in the clumping assay. Supernatants from E. coli strains expressing wild-type (WT) cCF10 (LVTLVFV) from pPCR-4 or each of the mutant peptides were assayed for activity (light bars) following overnight growth with aeration in LB medium. Activities of synthesized peptides (dark bars) were assayed from twofold serial dilutions of a 50-ng/ml stock solution.
|
![]() View larger version (10K): [in a new window] |
FIG. 5. PrgZ effects on p043lacZ induction ability of peptides. Synthetic cCF10 variant peptides were added at 5 ng/ml to cCF10-deficient strain JRC104 harboring p043lacZ with a second plasmid expressing PrgZ from pMSP6043-1 (Z+, dark bars) or a vector control, pMSP6043-2 (Z, light bars). Peptides were added immediately after a 1:5 dilution from stationary-phase cultures, and ß-galactosidase induction levels were measured after 90 min incubations. Data shown are representative of at least two independent experiments done in duplicate; error bars represent one standard deviation of the mean.
|
(this peptide was synthesized and tested, though it was not identified in the genetic screen), comprised of the first six residues of cCF10, exhibited a nearly undetectable pheromone activity (Fig. 4). From these data, we conclude that productive interactions with both PrgX and PrgZ have driven the evolution of the biological activity of the native cCF10 sequence and that the specific peptide sequence determinants for productive interaction with each protein do not overlap completely. |
|
|---|
The genetic screen carried out in this study identified 15 variants of cCF10 with amino acid substitutions. With a single exception (V7I), determination of the relative pheromone activities of all the synthetic cCF10 variants gave the same results as those obtained in the assays of E. coli supernatants. Although we limited our screen to testing about 600 clones from a total of three independent transformations, we did identify mutations resulting in the same amino acid sequence change in multiple independent transformants. This suggests that, given the phenotypic constraints used, we may have approached saturation in this screen.
Relative to cCF10, all of the synthetic peptides had reduced pheromone activity when tested against responder cells expressing PrgZ (Fig. 4 and 5). In most cases, the presence of PrgZ increased the absolute inducing activities of the variants in a fashion similar to that observed with cCF10. For the two peptides (T3S and F6Y) whose activity was not enhanced by PrgZ, it was concluded that the substitutions probably had no deleterious effects on the peptide interactions with PrgX (and even enhanced this interaction slightly in the case of F6Y). However, these variants had a reduced productive interaction with PrgZ, with the overall effect being a slight reduction of pheromone activity when the responder cells expressed both PrgZ and PrgX. Peptide V7I had a much higher increase in inducing activity when assayed against p043lacZ-containing responder cells containing PrgZ than all the other peptides, including native cCF10. In this case the mutation probably enhanced a productive interaction with PrgZ, resulting in increased import into the responder cell, but at the same time the interaction with PrgX was impaired slightly, reducing the overall activity. The molecular nature of "productive" peptide/PrgZ interaction that was affected in peptides T3S, F6Y, and V7I is essentially unknown. One formal possibility is that the optimal interactions could increase the binding affinity of the peptide for PrgZ. However kinetic studies of oligopeptide permease-mediated peptide import in Lactococcus lactis by the Poolman group (32) suggested the possibility that release of previously bound peptide from the OppA binding protein (PrgZ is an OppA homolog specific for cCF10) into the transmembrane channel formed by the other Opp components could be the rate-limiting step in peptide import. Comparative biochemical and structural studies of PrgZ interactions with cCF10 and the three variant peptides discussed above could help distinguish between these two possibilities. It is also formally possible that certain amino acid substitutions could affect efficiency of import by the chromosomal OppA binding protein, but we lack the tools to examine this possibility at present.
The majority of amino acid substitutions identified in this study appeared to affect peptide/PrgX interactions. Since all of these variants retained some pheromone activity but caused no detectable inhibition of cCF10, it is likely that they all produced structural changes in PrgX similar to those observed with cCF10 but that the binding affinities were reduced or the rotation of the C-terminal arm of PrgX that leads to destabilization of tetramers occurred to a lesser extent. Previous structural studies of PrgX suggested that nearly all of the hydrogen bonding interactions between the peptide and residues in the C-terminal domain of PrgX involve the peptide backbone, and this is also the case for many of the interactions between the peptide and the PrgX residues lining the binding pocket. This is consistent with the fact that there are almost no charged side groups in any of the residues of cCF10 or iCF10. The hydrophobic side chains of these peptides likely affect PrgX interactions either by providing spatial constraints or by affecting the binding affinity. The available structural data suggest some explanations for the results presented here. For example, the L4V substitution, which reduced the inducing activity by >95% in responder cells lacking PrgZ (Fig. 5), replaced a large hydrophobic side chain with a smaller one. The three-carbon valine side chain of L4V would easily fit within the space occupied by four-carbon leucine side chain of cCF10, and the formation of an important hydrogen bond between the peptide backbone and PrgX residue Y298 (39) should not be impaired in the variant. However, the smaller side chain would probably confer weaker hydrophobic interactions with the binding pocket, reducing affinity of the peptide for PrgX. Similar lines of reasoning can be used to suggest structural interactions to account for the activities of the other variant peptides, including F6Y, where the extra hydroxyl group on the aromatic side chain would not appear to cause any spatial problems and might actually provide an additional hydrogen bond with PrgX to stabilize the complex, accounting for its increased inducing activity (in cells lacking PrgZ). As noted above, these kind of predictions need to be verified experimentally. Our efforts to obtain quantitative solution binding affinity data have been hampered by the tendency for the peptides and protein to precipitate from aqueous solutions and to stick nonspecifically to dialysis membranes and other surfaces, but further structural and biochemical studies on these peptides are in progress.
Genetic analyses of signaling peptide specificity have been carried out in a few other systems, generally those involving membrane histidine kinase peptide receptors (12, 26, 27, 34). For the pneumococcal competence-stimulating peptide, genetic analyses have been coupled with solution structural analyses using spectroscopic techniques (27). In the case of the enterococcal pheromone peptides, the biological activities of synthetic peptides selected based on visual inspection of native pheromone sequences have been tested (28), but this was done before the identities of the sex pheromone receptors were actually proven. In the pAD1 system, An and Clewell synthesized cAD1 variants containing single alanine substitutions at each nonalanine residue and found that all of these except V5A dramatically reduced pheromone activity (2). The present study provides peptide reagents with a range of biological activities for a comprehensive high-resolution structure/function analysis of the pCF10 cell-cell signaling system.
We thank Ke Shi, Douglas Ohlendorf, and Cathleen Earhart for helpful discussions about this work.
Published ahead of print on 10 November 2006. ![]()
Present address: Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA. ![]()
Present address: Department of Microbiology, University of Washington, Seattle, WA. ![]()
Present address: Oregon Health and Science University, Department of Molecular Microbiology and Immunology, Portland, OR. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»